Myositis is inflammation of your skeletal muscles, which are also called the voluntary muscles. These are the muscles you consciously control that help you move your body. An injury, infection or autoimmune disease can cause myositis. The diseases dermatomyositis and polymyositis both involve myositis. Polymyositis causes muscle weakness, usually in the muscles closest to the trunk of your body. Dermatomyositis causes muscle weakness, plus a skin rash. Both diseases are usually treated with prednisone, a steroid medicine, and sometimes other medicines.
Dermatomyositis is an idiopathic inflammatory myopathy that has been regarded as an autoimmunity-based disorder, although its pathogenesis remains unclear.
The National Institute of Arthritis and Musculoskeletal and Skin Diseases has awarded UCI a 5-year, $4.2 million grant to study sporadic inclusion body myositis (sIBM), which affects aging adults causing asymmetric muscle weakness and severe disability. The disease is currently untreatable and poorly understood.
A new study by researchers at the University of Toronto and the University of Calgary in Canada indicates that the presence of these antibodies correlates with more severe COVID-19 symptoms and signs.
Muscle soreness and achy joints are common symptoms among COVID-19 patients. But for some people, symptoms are more severe, long-lasting, and even bizarre, including rheumatoid arthritis flares, autoimmune myositis, or "COVID toes."
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent for coronavirus disease 2019 (COVID-19), is associated with several clinical features common in autoimmune diseases as myalgias, arthralgias, fatigue, and rashes. COVID-19 patients also exhibit less common autoimmunity manifestations such as myositis, thrombosis, myocarditis, encephalitis, vasculitis, and arthritis.
The European League Against Rheumatism, EULAR, has published recommendations around rheumatic immune-related adverse events caused by cancer treatment with checkpoint inhibitors.
Autoimmunity, a condition in which the body's immune system reacts with components of its own cells, appears to be increasing in the United States, according to scientists at the National Institutes of Health and their collaborators.
Checkpoint inhibitor therapy is a form of cancer treatment immunotherapy currently under research. The therapy targets immune checkpoints, key regulators of the immune system that stimulate or inhibit its actions, which tumors can use to protect themselves from attacks by the immune system.
Cell death is an important aspect of tissue homeostasis, as well as inflammation and disease pathogenesis related to infection, injury, and tumor growth.
Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.
Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.
Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).
In early 2015, Mike Matthews, a teacher, social worker, and counselor for the State of Kentucky, experienced a constellation of apparently unrelated health problems that doctors could not diagnose. He lost more than thirty pounds, had trouble swallowing and speaking, developed a rash over his knuckles and other parts of his body, and experienced extreme muscle weakness and fatigue.
Dr. Lesley Ann Saketkoo, an associate professor of clinical medicine at Tulane University School of Medicine, has been named Doctor of the Year by the Scleroderma Foundation. The award recognizes leadership and commitment to the community battling scleroderma, a disabling and life-limiting multi-organ autoimmune disease with progressive lung, heart, kidney, gastrointestinal tract and/or vascular involvement.
Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.
Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.
Rheumatoid Arthritis: A systematic approach (edited by Dr. Syuichi Koarada) comprehensively covers each aspect of the pathology, diagnosis and treatment of rheumatoid arthritis.
Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.
Bristol-Myers Squibb Company today announced patient-reported outcomes data from the Phase 3 CheckMate -214 trial in intermediate- and poor-risk patients with advanced renal cell carcinoma treated with the Immuno-Oncology combination Opdivo plus low-dose Yervoy versus sunitinib over a two-year follow-up period.
The ability to diagnose myositis diseases and treat them properly just improved immensely. For more than 40 years, the criteria physicians have used to diagnose most myositis diseases has been based on expert opinion, not hard science.